{"id":1794,"date":"2022-09-19T10:48:31","date_gmt":"2022-09-19T07:48:31","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=1794"},"modified":"2022-09-19T12:02:45","modified_gmt":"2022-09-19T09:02:45","slug":"gliead-sciences-2","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=1794","title":{"rendered":"Gilead, Hepatit Hasta Gruplar\u0131 Aras\u0131nda Yap\u0131lan \u0130tibar Anketinde Bu Y\u0131l da Birinci"},"content":{"rendered":"

Ya\u015fam\u0131 tehdit eden hastal\u0131klara yenilik\u00e7i tedaviler geli\u015ftiren bilim \u015firketi Gilead, hepatit alan\u0131nda yapt\u0131\u011f\u0131 \u00e7al\u0131\u015fmalarla sekt\u00f6rde liderli\u011fini koruyor. D\u00fcnya \u00e7ap\u0131nda 111 hepatit hasta grubunun kat\u0131ld\u0131\u011f\u0131 2021 PatientView<\/strong> Corporate Reputation of Pharma (\u0130la\u00e7 \u015eirketlerinin Kurumsal \u0130tibar\u0131) anketinde Gilead, bu y\u0131l da ilk s\u0131rada yer ald\u0131.\u00a0<\/strong><\/p>\n

Hasta gruplar\u0131n\u0131n ihtiya\u00e7lar\u0131n\u0131n nas\u0131l kar\u015f\u0131lad\u0131\u011f\u0131n\u0131 \u00f6l\u00e7\u00fcmlemek \u00fczere \u00e7ok say\u0131da tedavi alan\u0131nda gruplar\u0131n g\u00f6r\u00fc\u015fleriyle ba\u011f\u0131ms\u0131z bir rapor olarak haz\u0131rlanan PatientView Corporate Reputation of Pharma, 2010 y\u0131l\u0131ndan bu yana her y\u0131l yay\u0131mlan\u0131yor. \u00a0Gilead, 1,8 milyon hasta toplulu\u011fuyla ileti\u015fim halinde olan ve hepatit veya karaci\u011fer rahats\u0131zl\u0131klar\u0131ndan etkilenen 111 hasta grubu taraf\u0131ndan yan\u0131tlanan ankette ilk s\u0131rada yer ald\u0131. Gilead\u2019\u0131n son \u00fc\u00e7 y\u0131ld\u0131r ilk s\u0131radaki yerini korumas\u0131, t\u00fcm d\u00fcnyan\u0131n her yerinde hastalar\u0131n ihtiya\u00e7lar\u0131na \u00e7\u00f6z\u00fcm sunmak ve ya\u015fam kalitesini art\u0131rmak i\u00e7in g\u00f6sterdi\u011fi \u00e7abalar\u0131n ve hasta odakl\u0131 yakla\u015f\u0131m\u0131n\u0131n g\u00f6stergesi.<\/p>\n

Gilead, ankette viral hepatitten etkilenen topluluklar\u0131 e\u011fitmek, topluma kazand\u0131rmak ve g\u00fc\u00e7lendirmek \u00fczerine belirlenen 10 kurumsal itibar g\u00f6stergesinin tamam\u0131nda ilk s\u0131rada yer ald\u0131:<\/p>\n

    \n
  1. \u00a0 \u00a0 \u00a0 \u00a0 Covid-19 pandemisinde hastalar\u0131 destekleme<\/li>\n
  2. \u00a0 \u00a0 \u00a0 \u00a0 Etkili hasta merkezli strateji<\/li>\n
  3. \u00a0 \u00a0 \u00a0 \u00a0 Nitelikli hasta bilgileri<\/li>\n
  4. \u00a0 \u00a0 \u00a0 \u00a0 Hasta g\u00fcvenli\u011fi kayd\u0131<\/li>\n
  5. \u00a0 \u00a0 \u00a0 \u00a0 Kullan\u0131\u015fl\u0131, y\u00fcksek kaliteli \u00fcr\u00fcnler<\/li>\n
  6. \u00a0 \u00a0 \u00a0 \u00a0 Fiyatland\u0131rma, klinik veriler ve d\u0131\u015f payda\u015flar\u0131n finansman\u0131na ili\u015fkin \u015feffafl\u0131k<\/li>\n
  7. \u00a0 \u00a0 \u00a0 \u00a0 D\u00fcr\u00fcstl\u00fck<\/li>\n
  8. \u00a0 \u00a0 \u00a0 \u00a0 Hasta-grup ili\u015fkileri<\/li>\n
  9. \u00a0 \u00a0 \u00a0 \u00a0 Tedavinin \u00f6tesinde hizmetler sunma<\/li>\n
  10. \u00a0 \u00a0 \u00a0 Hastalar\u0131 ara\u015ft\u0131rma ve geli\u015ftirmeye dahil etme<\/li>\n<\/ol>\n

    \"\"Gilead Pazara Eri\u015fim ve Kurumsal \u0130li\u015fkiler Direkt\u00f6r\u00fc Toros \u015eahin<\/strong>, \u201cHepatit, Gilead olarak \u00f6ncelikli tedavi alanlar\u0131m\u0131zdan biri. Bu alanda s\u00fcrd\u00fcrd\u00fc\u011f\u00fcm\u00fcz yenilik\u00e7i \u00e7al\u0131\u015fmalar\u0131m\u0131z\u0131n \u00f6zellikle hasta gruplar\u0131 nezdinde takdir edildi\u011fini g\u00f6rmek gurur verici. Hepatit C alan\u0131nda v\u00fccudumuzdan vir\u00fcs\u00fcn tamamen ar\u0131mas\u0131n\u0131 sa\u011flayan tedaviyi ve hepatit B alan\u0131nda d\u00fcnyada FDA ve EMA taraf\u0131ndan en son onaylanan tedaviyi kullan\u0131ma sunduk. Gilead T\u00fcrkiye olarak \u201cT\u00fcrkiye i\u00e7in T\u00fcrkiye\u2019de\u201d diyerek yapt\u0131\u011f\u0131m\u0131z yat\u0131r\u0131mla yerli \u00fcretime ba\u015flad\u0131k. Geli\u015ftirdi\u011fimiz en son Hepatit B ilac\u0131m\u0131z\u0131 da bu kapsamda T\u00fcrkiye\u2019de \u00fcretmeye ba\u015flayarak bu y\u0131l\u0131n ba\u015f\u0131nda hastalar\u0131n kullan\u0131m\u0131na sunduk.\u00a0Di\u011fer yandan hepatit B konusunda toplumsal fark\u0131ndal\u0131\u011f\u0131 art\u0131rmak, d\u00fczenli tedavi ve sa\u011fl\u0131k kontrollerinin \u00f6nemine dikkat \u00e7ekmek i\u00e7in ba\u015flatt\u0131\u011f\u0131m\u0131z HEP VAR fark\u0131ndal\u0131k kampanyam\u0131z i\u00e7in bir web sitesi olu\u015fturduk (www.hepvar.com<\/a>). Web sitemizde hepatit belirtileri, t\u00fcrleri, test ve tedavi s\u00fcre\u00e7leri gibi temel bilgilerin yan\u0131 s\u0131ra hepatit B hakk\u0131nda en \u00e7ok merak edilen sorular\u0131n yan\u0131tland\u0131\u011f\u0131 hekim videolar\u0131 ve tan\u0131 konan hastalar\u0131n deneyimleri yer al\u0131yor. Bu web sitesiyle ba\u015fta hepatit B hastalar\u0131 ve yak\u0131nlar\u0131 olmak \u00fczere t\u00fcm toplumu bilgilendirmek ve bu alanda fark\u0131ndal\u0131\u011f\u0131 art\u0131rmay\u0131 hedefliyoruz\u201d dedi.<\/p>\n

     <\/p>\n","protected":false},"excerpt":{"rendered":"

    Ya\u015fam\u0131 tehdit eden hastal\u0131klara yenilik\u00e7i tedaviler geli\u015ftiren bilim \u015firketi Gilead, hepatit alan\u0131nda yapt\u0131\u011f\u0131 \u00e7al\u0131\u015fmalarla sekt\u00f6rde liderli\u011fini koruyor. D\u00fcnya \u00e7ap\u0131nda 111 hepatit hasta grubunun kat\u0131ld\u0131\u011f\u0131 2021 PatientView Corporate Reputation of Pharma (\u0130la\u00e7 \u015eirketlerinin Kurumsal \u0130tibar\u0131) anketinde Gilead, bu y\u0131l da ilk s\u0131rada yer ald\u0131.\u00a0 Hasta gruplar\u0131n\u0131n ihtiya\u00e7lar\u0131n\u0131n nas\u0131l kar\u015f\u0131lad\u0131\u011f\u0131n\u0131 \u00f6l\u00e7\u00fcmlemek \u00fczere \u00e7ok say\u0131da tedavi alan\u0131nda gruplar\u0131n …<\/p>\n","protected":false},"author":1,"featured_media":1802,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,3],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/1794"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1794"}],"version-history":[{"count":1,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/1794\/revisions"}],"predecessor-version":[{"id":1801,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/1794\/revisions\/1801"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/1802"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}